Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 118-124

  Germanaud, David ^a   Derache, Anne ^b   Traore, Mamadou ^c   Madec, Yoann ^d   Toure, Safiatou ^c   Dicko, Fatoumata ^c   Coulibaly, Hadizatou ^c   Traore, Malick ^e   Sylla, Mariam ^c   Calvez, Vincent ^b   Marcelin, Anne Genevieve ^b  

^a SOLTHIS   (Mali)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL GABRIEL TOURÉ   (Mali)

^d INSTITUT PASTEUR   (France)

^e Institut National de Recherche en Sante Publique Mali   (Mali)

Author keywords

Africa; Failure; Mutations

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; EFAVIRENZ; ISOLEUCINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LEUCINE; LYSINE; METHIONINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRYPTOPHAN; VALINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MALI; PATIENT COMPLIANCE; PROSPECTIVE STUDY; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION; WILD TYPE;

EID: 77950353556     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp412     Document Type: Article

References (22)

1. Descamps D, Flandre P, Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA 2000; 283: 205-11.
2. Havlir DV, Hellmann NS, Petropoulos CJ et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283: 229-34.
3. Marcelin AG, Jarrousse B, Derache A et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. AIDS 2007; 21: 2341-3.
4. Marconi VC, Sunpath H, Lu Z et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46: 1589-97.
5. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298: 1888-99.
6. Cowburn C, Hatherill M, Eley B et al. Short-term mortality and implementation of antiretroviral treatment for critically ill HIV-infected children in a developing country. Arch Dis Child 2007; 92: 234-41.
7. Ellis J, Molyneux EM. Experience of anti-retroviral treatment for HIV-infected children in Malawi: the 1st 12 months. Ann Trop Paediatr 2007; 27: 261-7.
8. Kabue MM, Kekitiinwa A, Maganda A et al. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS 2008; 22: 245-51.
9. O'Brien DP, Sauvageot D, Zachariah R et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 2006; 20: 1955-60.
10. van Kooten Niekerk NK, Knies MM, Howard J et al. The first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy. J Trop Pediatr 2006; 52: 3-11.
11. Fassinou P, Elenga N, Rouet F et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS 2004; 18: 1905-13.
12. Reddi A, Leeper SC, Grobler AC et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr 2007; 7: 13.
13. Song R, Jelagat J, Dzombo D et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics 2007; 120: e856-61.
14. Wamalwa DC, Farquhar C, Obimbo EM et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr 2007; 45: 311-7.
15. Adje-Toure C, Hanson DL, Talla-Nzussouo N et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 2008; 24: 911-7.
16. Descamps D, Delaugerre C, Masquelier B et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78: 153-60.
17. Reddi A, Leeper SC. Antiretroviral therapy adherence in children: outcomes from Africa. AIDS 2008; 22: 906-7.
18. Puthanakit T, Aurpibul L, Sirisanthana T et al. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less. Ped Infect Dis 2009; 28: 246-8.
19. Puthanakit T, Oberdorfer A, Akarathum N et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005; 41: 100-7.
20. Mouroux M, Descamps D, Izopet J et al. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antivir Ther 2001; 6: 179-83.
21. Derache A, Maiga AI, Traore O et al. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 2008; 62: 456-63.
22. Derache A, Traore O, Koita V et al. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther 2007; 12: 123-9